Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Exagen Inc. (XGN) reported a Q3 loss of $0.28 per share, slightly better than the Zacks Consensus Estimate of a $0.30 loss, but missed revenue estimates.
November 12, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Exagen Inc. reported a Q3 loss of $0.28 per share, which was better than the expected $0.30 loss, but the company missed revenue estimates.
Exagen's reported loss per share was slightly better than expected, which is a positive sign. However, missing revenue estimates could offset this positive news, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100